The NUDT5 Knockout Raji Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, enabling loss-of-function studies of NUDT5. This polyclonal format retains heterogeneous genetic edits across the population, avoiding clonal artifacts while disrupting NUDT5 gene function. The cells are designed for researchers investigating the molecular roles of NUDT5 in DNA damage repair, ADP-ribose signaling, and B-cell lymphoma biology. They serve as a validated experimental model for pathway dissection and drug response profiling.
The Raji host cell line is an Epstein-Barr virus (EBV)-transformed B lymphocyte originally isolated from a Burkitt’s lymphoma patient. These cells are extensively used as a model for B-cell lymphoma, immune response studies, and EBV latency research. Raji cells exhibit characteristic features of B-cell malignancies, including c-MYC deregulation, and are sensitive to DNA-damaging agents. Their robust proliferation and well-characterized signaling networks make them a suitable background for evaluating the impact of NUDT5 disruption on lymphoma-relevant phenotypes.
NUDT5 encodes an ADP-ribose pyrophosphatase that hydrolyzes free ADP-ribose to AMP and ribose-5-phosphate, a critical reaction controlling nuclear ADP-ribose levels and NAD+ metabolism. The enzyme functions downstream of poly(ADP-ribose) polymerases (PARP1/2), which generate ADP-ribose polymers, and counterbalances PARG and ARH3 glycohydrolase activities. NUDT5 interacts with PARP1, XRCC1, and histones, modulating ADP-ribosylation marks on DNA repair and chromatin proteins. In the polyclonal knockout cells, NUDT5 disruption impairs ADP-ribose hydrolysis, leading to accumulation of free ADP-ribose, altered PARP-mediated signaling, and potential deregulation of DNA repair complexes and chromatin remodeling. Additionally, NUDT5 has been implicated in redox homeostasis and may influence nucleotide catabolism, linking its loss to metabolic reprogramming in B-cells.
In the context of Raji B lymphocytes, NUDT5 knockout provides a powerful tool for dissecting ADP-ribose-dependent mechanisms in lymphoma. The disruption may sensitize cells to PARP inhibitors by exacerbating DNA repair deficiencies, or it could reveal compensatory pathways that contribute to drug resistance. Moreover, since Raji cells maintain EBV latency, this model permits exploration of how ADP-ribose metabolism intersects with viral persistence and oncogenic signaling. The loss of NUDT5 may alter histone ADP-ribosylation patterns, influencing gene expression programs involved in B-cell survival and proliferation, thus shedding light on novel therapeutic targets in B-cell malignancies.
Researchers can employ this polyclonal knockout model in a wide range of assays, including western blotting and RT-qPCR for validation of NUDT5 disruption, flow cytometry to assess cell cycle and apoptosis changes, and immunofluorescence detection of ??H2AX foci to quantify DNA damage. Metabolic assays measuring NAD+ levels and drug sensitivity testing with PARP inhibitors (e.g., olaparib) can probe the functional consequences on ADP-ribose signaling. Transcriptomic analysis via RNA-seq enables unbiased profiling of pathway alterations. These applications support investigations into NUDT5’s roles in lymphoma pathogenesis, PARP inhibitor resistance, and EBV latency. For additional technical information or custom inquiries, please contact Ascent Research.
